CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00434031

Acronym

CETRA

Enrollment

Registered

2007-02-12

Start date

2007-09-30

Completion date

Unknown

Last updated

2012-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

locally advanced, stage II, stage IIIa, stage IIIb, HER-2 positive, primary

Brief summary

The purpose of this study is to evaluate the rate of pathologic complete response when giving docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and trastuzumab before surgery in treating women with operable or locally advanced HER-2 positive breast cancer.

Detailed description

Chemotherapy in association with trastuzumab, a monoclonal antibody, given before surgery, has been shown to reduce tumor size and permit better resection of HER-2 positive breast cancers. This study will evaluate the activity of a neoadjuvant treatment with docetaxel and trastuzumab given every 3 weeks for 4 cycles, followed by the combination of caelyx, cyclophosphamide and trastuzumab every 3 weeks for 4 cycles. Patients will undergo breast cancer surgery 2-5 weeks after the completion of neoadjuvant therapy. Adjuvant therapy after surgery will be given according to existing guidelines, and will include an additional 10 cycles of trastuzumab.

Interventions

DRUGdocetaxel

DRUGcyclophosphamide

DRUGtrastuzumab

DRUGliposomal doxorubicin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Histological diagnosis of breast cancer * Stage II-IIIB (T0-1-2-3-4-N+-M0 or T2-3-4-N0-M0; according to TNM AJCC classification, 2002) * Hyperexpression of HER-2/neu (HercepTest 3+ or positive FISH test) * Age\> 18 e \< 65 years * Left ventricular ejection fraction (LVEF) \> or = 55% * ECOG Performance Status 0-2 * Neutrophils \> or = 2000/mm³, platelets \> or = 100.000/mm³ , hemoglobin \> or = 10 g/dl), GOT, GPT and bilirubin \< 1.25 x the upper normal limit, creatinine \< 1.25 x the upper normal limit. * Life expectancy \> 3 months * Signed informed consent.

Exclusion criteria

* Any prior treatment for breast cancer * Metastatic disease (M1) * Performance status (ECOG) \> or = 3 * Current malignancy or history of prior malignancy within past 10 years (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ of the uterine cervix) * Neutrophils \< 2.000/mm³ , platelets \< 100.000/mm³ , hemoglobin \< 10 g/dl. * Creatinine \> 1.25 x the upper normal limit * GOT and/or GPT and/or bilirubin \>1.25 x the upper normal limit. * Concomitant conditions that, in the investigator's opinion, contraindicate the use of the drugs in the protocol. * Congestive heart failure or history of congestive heart failure, unstable angina pectoris, myocardial infarction, clinically significant valvulopathy or uncontrolled arrhythmias * Active infection * Incapacity or refusal to provide informed consent. * Inability to comply with follow up * Pregnant or nursing females.

Design outcomes

Primary

Measure	Time frame
complete pathologic response rate	—

Secondary

Measure	Time frame
toxicity of neoadjuvant treatment	—
predictive ability of noninvasive diagnostic methods for results of neoadjuvant treatment	—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026